Subject matters | Details | Categories |
---|---|---|
Health, Research and Development
|
Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
|
Policies or Program
|
Health, Research and Development
|
Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
|
Policies or Program, Regulation
|
Intellectual Property, International Trade
|
Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
|
Policies or Program, Regulation
|
Federal-Provincial Relations, Health
|
Communications regarding national pharmacare legislation, regulations, policies or programs.
|
Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
|
Health
|
Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
|
Policies or Program
|
Health
|
Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
|
Policies or Program
|
Health, Research and Development
|
Communications with Health Canada regarding guidelines for pediatric action plans.
|
Policies or Program
|
Health, Research and Development
|
Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
|
Regulation, Policies or Program
|
Health
|
Communications with Health Canada regarding the application of its nitrosamine guidelines.
|
Policies or Program
|
Health, Research and Development
|
Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
|
Regulation, Policies or Program
|
Health, Research and Development
|
Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
|
Policies or Program, Regulation
|
Health, International Trade
|
Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
|
Policies or Program
|
Aboriginal Affairs, Health
|
Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
|
Policies or Program
|
Economic Development, Industry, Research and Development
|
Innovation, Science and Economic Development (ISED)'s Biomanufacturing and Life Sciences Strategy, pertaining to growth and development of the life sciences industry in Canada.
|
Policies or Program
|
Economic Development, Health, Industry, Intellectual Property
|
Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
|
Policies or Program
|
Aboriginal Affairs, Health
|
Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
|
Policies or Program
|
Health
|
The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
|
Policies or Program
|
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca.
RAMI FAYED, Vice President and General Manager, Canada
Address:
8401 Transcanada Highway
St-Laurent, QC H4S 1Z1
Canada
Telephone number:
888-703-3006
AbbVie Corporation does not have any subsidiaries that could have a direct interest in the outcome of the undertaking